Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Myriad Genetics Inc. ownership filing shows State Street Corporation beneficially owned 4,424,027 shares of Common Stock, representing 4.7% of the class as of 03/31/2026. The filing reports shared voting power of 4,164,534 shares and shared dispositive power of 4,424,027.
The submission is a Schedule 13G indicating passive investment classification and lists related State Street advisory entities; signature dated 05/12/2026.
Myriad Genetics reported modest Q1 2026 revenue growth but a larger net loss. Revenue rose to $200.4 million from $195.9 million, driven by stronger Mental Health sales and higher Cancer Care Continuum volume, partially offset by lower Prenatal Health revenue.
The company posted a net loss of $34.1 million versus near breakeven a year ago, mainly due to the absence of a prior one-time tax benefit and a $5.4 million goodwill and long‑lived asset impairment. Operating loss was $30.7 million compared with $29.0 million. Cash and cash equivalents declined to $124.4 million from $149.6 million, with operating cash outflow of $15.7 million. Long‑term debt remained around $125.0 million under a SOFR‑based term loan maturing in 2030.
Myriad Genetics reported first quarter 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in Cancer Care Continuum and Mental Health testing that offset weaker Prenatal Health demand. Total test volumes were 385,000, flat year-over-year, with mix shifting toward oncology and mental health.
The company posted a GAAP net loss of $34.1 million, or $0.36 per share, while adjusted loss per share was $0.09 and adjusted EBITDA was $(4.5) million. Management reiterated full-year 2026 guidance for revenue of $860–$880 million and adjusted EBITDA of $37–$49 million, and ended the quarter with $124.4 million in cash and cash equivalents.
MYRIAD GENETICS INC Chief Commercial Officer Brian J. Donnelly had 55,975 shares of Common Stock withheld at $4.80 per share to cover tax obligations. These shares were withheld in connection with the vesting of previously granted restricted stock units, and he now directly holds 568,363 shares.
Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-withholding disposition of company stock. On April 14, 2026, 1,069 shares of Myriad Genetics common stock were withheld by the company at $4.91 per share to cover his tax obligations from previously granted restricted stock units vesting. After this withholding, Verratti directly holds 629,646 shares of Myriad Genetics common stock, indicating that the transaction represents a very small portion of his overall equity position and does not reflect an open-market sale.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-withholding transaction tied to equity compensation. On April 14, 2026, 946 shares of Common Stock were withheld by the company at $4.91 per share to cover tax obligations from previously granted restricted stock units vesting. After this withholding, Muzzey directly holds 326,310 shares of Myriad Genetics common stock.
Myriad Genetics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026. Proposals include electing three Class III directors, ratifying Ernst & Young as auditor, an advisory vote on executive pay, and approving an amended 2012 Employee Stock Purchase Plan plus a new 2026 equity incentive plan.
In 2025, the company generated $824.5 million in revenue, a 2% decline from 2024, and reported a GAAP net loss of $365.9 million, while producing adjusted EBITDA of $38.9 million and adjusted EPS of $0.06. Total test volumes grew 1%, led by 7% growth in hereditary cancer testing and 6% growth in mental health testing.
The “New Myriad” strategy focuses on the Cancer Care Continuum, with launches planned for the Precise MRD platform, an AI‑enabled Prolaris prostate cancer test and the FirstGene prenatal screen in 2026. Management expects annual revenue growth to accelerate to high‑single‑digit to low‑double‑digit percentages over the mid‑ to long‑term while redirecting and investing more than $35 million into commercial capabilities and key R&D programs.
BlackRock, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting ownership of 7,976,163 shares of Myriad Genetics, Inc. Common Stock as of 03/31/2026. The filing shows 7,841,058 shares of sole voting power and 7,976,163 shares of sole dispositive power, representing 8.5% of the class.
The submission is an institutional beneficial‑ownership disclosure that aggregates holdings of reporting business units of BlackRock, Inc. and is signed by a Managing Director on 04/07/2026.
Myriad Genetics Inc ownership disclosure: The Vanguard Group filed Amendment No. 14 to its Schedule 13G/A stating it beneficially owns 0 shares of Myriad Genetics common stock, representing 0% of the class. The filing explains an internal realignment and separate reporting by certain Vanguard subsidiaries.